Canada Markets open in 5 hrs 56 mins

Orchard Therapeutics plc (ORTX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
0.5700-0.0142 (-2.43%)
At close: 04:00PM EDT
0.5900 +0.02 (+3.51%)
After hours: 07:36PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close0.5842
Open0.5700
Bid0.5733 x 29200
Ask0.5900 x 3100
Day's Range0.5600 - 0.6200
52 Week Range0.4100 - 4.2900
Volume1,417,680
Avg. Volume743,432
Market Cap71.534M
Beta (5Y Monthly)1.15
PE Ratio (TTM)N/A
EPS (TTM)-1.2120
Earnings DateFeb 28, 2022 - Mar 04, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.14
  • GlobeNewswire

    Orchard Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Commercial Progress

    Product sales for Libmeldy totaled $5.1M for the first two commercial patients treated in Q1 2022 Libmeldy® access and reimbursement expanding with agreements now signed in three major European markets recognizing its clinical value OTL-200 U.S. BLA filing for MLD on track for late 2022 / early 2023 Seven upcoming presentations at ASGCT highlight application of HSC approach including clinical and research programs Cash and investments of approximately $200M provide runway into 2024 BOSTON and LO

  • GlobeNewswire

    Orchard Therapeutics Announces Presentations at ASGCT 2022 Showcasing Potential of HSC Gene Therapy in Neurodegenerative Disorders and Beyond

    BOSTON and LONDON, May 10, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today outlined seven presentations from across its platform to be featured at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting taking place May 16-19 in Washington, D.C. Featured presentations include updated results on the OTL-203 clinical program for mucopolysaccharidosis type I Hurler syndrome (MPS-IH), as well as several accepted abstracts highlighting

  • GlobeNewswire

    Orchard Therapeutics to Webcast Conference Call of First Quarter 2022 Financial Results

    BOSTON and LONDON, May 05, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company will host a conference call and live webcast on Thursday, May 12, 2022, at 8:00 a.m. ET to review business updates and its first quarter 2022 financial results. A live webcast will be available under "News & Events" in the Investors & Media section of the company's website at www.orchard-tx.com. The conference call can be accessed by dialing +1 (